In the rule, CMS said that it would lower the maximum co-pay amount for low-income subsidy (LIS) beneficiaries for biosimilar and interchangeable biosimilars to match the lower co-pay amount required for generic and preferred multiple-source drugs.
CMS has released its final rule for the Medicare program for the contract year 2019, and it includes a key change to its approach to biosimilars.
In the rule, CMS said that it would lower the maximum co-payment amount for low-income subsidy (LIS) beneficiaries for biosimilar and interchangeable biosimilars to match the lower co-pay amount required for generic and preferred multiple-source drugs.
This rule represents a change from CMS’ previous proposal to include biosimilars and interchangeable biosimilars under a revised definition of “generic drugs” for the purposes LIS beneficiaries’ cost sharing. The rule indicates that CMS was concerned that misinterpretations of a revised definition of generics could create confusion about the broader treatment of biosimilar products and interchangeable biosimilars. Under the final rule, “CMS achieves the same goal intended by our original proposal, but now does so without the confusion that would result from defining biosimilar and interchangeable biological products as generic drugs for this limited purpose,” reads the rule.
CMS was careful to point out that its change of approach only applies to cost sharing, and “This policy does not change or supersede our existing formulary requirements for biosimilar biological products.”
However, CMS noted that it “does not have the flexibility” to establish a lower co-pay amount for biosimilars and interchangeable biosimilars for non-LIS enrollees who are in the catastrophic phase of the Medicare Part D benefit, however, and “given the high cost of biological products in general, the non-LIS catastrophic cost sharing will almost certainly be [5%].”
According to CMS, this new policy will reduce spending by approximately $10 million (and that the overall provisions of the final rule will save $123.6 million). It also noted that its approach to biosimilars will “reduce confusion in the marketplace surrounding this issue, [and] will improve enrollee protections while also improving enrollee incentives to choose biosimilar and interchangeable biological products over reference biological products.”
Finally, in response to comments urging CMS to revisit treatment of biosimilars and interchangeable biologics for the purpose of mid-year formulary changes, CMS clarified the fact that, as yet, there are no interchangeable biosimilars approved in the United States, and that, when “interchangeable biological products become available, we would consider whether additional regulatory changes would be warranted.”
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
BioRationality: Commemorating the 15th Anniversary of the BPCIA
April 8th 2025Affirming that analytical characterization is often sufficient for biosimilar approval, minimizing unnecessary clinical testing, and enhancing FDA-led education to counter stakeholder misconceptions are key recommendations put forth in this opinion piece by Sarfaraz K. Niazi, PhD.